Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment.
The hematopoietic growth factors are under investigation for the treatment of patients with chemotherapy-induced bone marrow suppression. One such trial at the University of California, Los Angeles involves chemotherapy with or without granulocyte colony-stimulating factor (G-CSF) in patients with small cell lung cancer. The authors report a case of a patient who had bullous pyoderma gangrenosum at the site of previous eczema during treatment with G-CSF. The lesions resolved promptly when the drug was discontinued. Other investigators have recently reported inflammatory complications of G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF) but this is the first case report of biopsy-proven neutrophilic dermatosis associated with administration of a hematopoietic growth factor. Patients should be monitored for development of inflammatory processes during G-CSF therapy and this therapy should be given with caution to those patients with existing inflammatory conditions.
Ross
H J
HJ
Department of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles 90024.
Moy
L A
LA
Kaplan
R
R
Figlin
R A
RA
D018288:Carcinoma, Small Cell / Q000628:therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D008875:Middle Aged; D011711:Pyoderma / Q000209:etiology*; D012883:Skin Ulcer / Q000209:etiology*
D016179:Granulocyte Colony-Stimulating Factor